Expansile nanoparticles could treat lung cancer patients unsuited for surgery
This article was originally published in Clinica
Executive Summary
A new type of nanoparticle that allows targeted intracellular drug delivery is under development as a possible therapy for lung cancer.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.